The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for ranibizumab (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
ranibizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
solution for injection
Indication
For the treatment of preterm infants with retinopathy of prematurity (ROP)
Therapeutic area
Ophthalmology